

Please try another search
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company’s lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Nadine Coulm | 58 | 2015 | Independent Director |
Jean Mariani | 71 | 2016 | Chief Medical Officer, Chairman of Scientific Advisory Board & Director |
Stanislas Veillet | 56 | 2015 | Chairman of the Board & CEO |
Rene Lafont | 76 | 2011 | Scientific Advisor & Member of Scientific Advisory Board |
Thomas Voit | - | 2017 | Member of Scientific Advisory Board |
Jose-Alain Sahel | - | - | Member of Scientific Advisory Board |
Ivana Kim | - | 2016 | Member of Scientific Advisory Board |
Roger A. Fielding | - | 2016 | Member of Scientific Advisory Board |
Claude Allary | 67 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review